How it works

Think of dendritic cells as your immune system's scouts. They patrol the body, and when they spot something that doesn't belong, they don't fight it themselves - they carry a sample back to the rest of the immune system and report exactly what to attack. Cancer is often good at slipping past unnoticed. This vaccine changes that.

The vaccine, called intismeran, is built from a sample of the patient's own tumor. Doctors sequence it to find the specific markers unique to that person's cancer, and Moderna uses AI to help identify which markers are most likely to trigger a strong immune response.² The vaccine then hands the patient's own dendritic cells a clear picture of what to look for - so the scouts know exactly what to report, and the body's T-cells know exactly what to attack.²

The trial, and what's next

The trial involved about 1,100 people with advanced melanoma that had already been surgically removed. Patients received either the vaccine alongside the immunotherapy drug Keytruda, or Keytruda alone. Those who got the combination had a lower risk of their cancer coming back or spreading.¹ ⁴

This isn't approved for general use yet - Moderna and Merck are moving toward filing for approval based on these results, and more detailed data is expected at an upcoming medical conference.² The companies are already testing the same personalized approach in other cancers, including lung, bladder, and kidney cancer, with the goal of expanding this kind of treatment well beyond melanoma.⁴ ⁶ If the results hold up in further trials, this could mark the start of personalized cancer vaccines becoming available to far more patients, not just those with melanoma.

What this could mean for patients ahead

For patients and families managing a melanoma diagnosis, or watching this space because of a family history, this is a meaningful signal - personalized, genomically matched treatment is moving from theory into practice.

What to do next

If you or a family member are managing a melanoma diagnosis and want to understand how developments like this apply to your situation, a medical second opinion can clarify whether your current treatment plan reflects the latest evidence.

Or call 647-350-5500 to speak with our team

Raymond Rupert | CEO

RCM Health Consultancy Inc.

647-350-5500 | info@rcmhealth.ca | rcmhealth.ca

References

1. Merck and Moderna say cancer vaccine shows promise in preventing recurrence of melanoma. NBC News, August 2026.
2. Moderna cancer vaccine stops melanoma returning: what's next for personalized treatments? Nature, August 2026.
3. Advances in mRNA-Based Melanoma Vaccines: A Narrative Review of Lipid Nanoparticle and Dendritic Cell Delivery Platforms. Cells, January 2026.
4. Moderna, Merck cancer vaccine shows initial late-stage melanoma data. CNBC, August 2026.
5. Moderna and Merck say melanoma vaccine succeeded in large trial. CNN, August 2026.
6. Moderna, Merck breakthrough could usher in wave of cancer vaccines. CNN, August 2026.

This article is for general information only and is not a substitute for individualized medical advice. Risk factors, assessment suitability, and treatment decisions are determined in consultation with your treating physician.